Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
ST Sutanto, R Sinto, A Pasaribu… - Acta Medica …, 2022 - europepmc.org
Coronavirus disease 2019 (COVID-19) is a respiratory tract disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). With the complexity of multimorbidity in …
respiratory syndrome coronavirus 2 (SARS-CoV-2). With the complexity of multimorbidity in …
Sustained Cytotoxic Response of Peripheral Blood Mononuclear Cells from Unvaccinated Individuals Admitted to the ICU Due to Critical COVID-19 Is Essential to …
G Casado-Fernández, M Corona, M Torres… - International journal of …, 2023 - mdpi.com
The main objective of this study was to determine the influence of the cytotoxic activity of
peripheral blood mononuclear cells (PBMCs) on the outcome of unvaccinated individuals …
peripheral blood mononuclear cells (PBMCs) on the outcome of unvaccinated individuals …
Analysis of the Structural Transformations Underlying the Design of Innovative Next-in-Class Drugs
KV Balakin - Russian Journal of General Chemistry, 2023 - Springer
Most of modern innovative drug compounds are not the new molecular structures, but
modified analogs of already known structures. The most successful chemotypes have been …
modified analogs of already known structures. The most successful chemotypes have been …
The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients
Enzyme inhibitors are frequently used to treat viral illnesses. Protease inhibitors are a
promising class for combating novel and life-threatening viral infections. This research …
promising class for combating novel and life-threatening viral infections. This research …
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in Scotland
M Drysdale, H Tibble, V Patel, DC Gibbons, E Lloyd… - medRxiv, 2023 - medrxiv.org
Introduction: Severe acute respiratory syndrome coronavirus 2 is constantly evolving. The
clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating …
clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating …
Population pharmacokinetics and pharmacodynamics of nirmatrelvir in Chinese patients with COVID‐19
L Zeng, R Chen, X Jiang, F Li, Z Zhu… - Fundamental & …, 2024 - Wiley Online Library
Background The pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of
nirmatrelvir (NMV) are unknown in Chinese patients with COVID‐19. Objectives To …
nirmatrelvir (NMV) are unknown in Chinese patients with COVID‐19. Objectives To …
Antibiotics and therapeutic agent prescription in COVID-19 management
S Zayet, T Klopfenstein - Antibiotics, 2022 - mdpi.com
During the coronavirus disease 2019 (COVID-19) pandemic, only few therapeutic options
have been approved for the treatment of COVID-19 with substantial evidence. The spectrum …
have been approved for the treatment of COVID-19 with substantial evidence. The spectrum …
[PDF][PDF] Unlocking Therapeutic Potential: Identifying Small Molecule Inhibitors for SARS-COV-2 Variants' Main Protease (MPRO) Through Molecular Docking Analysis
CYIE WOON, NI ISMAIL - Sains Malaysiana, 2024 - ukm.my
Even with existing emergency drugs, the development of safer and more effective drugs for
the treatment of COVID-19 still needs to continue. Virtual screening through a molecular …
the treatment of COVID-19 still needs to continue. Virtual screening through a molecular …
A Simple and Rapid LC‐MS/MS Method for the Quantification of Nirmatrelvir/Ritonavir in Plasma of Patients with COVID‐19
X Zhu, L Li, B Dai, Z Liu, Z Wang, L Cui… - … Journal of Analytical …, 2024 - Wiley Online Library
The combined prescriptions of nirmatrelvir/ritonavir and other drugs are limited due to
potential drug‐drug interactions, so therapeutic drug monitoring (TDM) becomes particularly …
potential drug‐drug interactions, so therapeutic drug monitoring (TDM) becomes particularly …